

THE FOLLOWING DRUGS WILL BE REVIEWED AT THE  
DRUG UTILIZATION REVIEW BOARD MEETING

March 26, 2015

Georgia Department of Community Health

**\*This list may change at any time. If a supplemental rebate class is not listed below, the class will be reviewed at the June 4<sup>th</sup> meeting. In addition, any drugs/classes listed below that the DURB is not able to complete at the March 26<sup>th</sup> meeting will be reviewed at the June 4<sup>th</sup> meeting. Manufacturers that already presented these drugs at the February Manufacturers' Forum will not need to present again at the April Manufacturers' Forum. Information on the Manufacturers' Forum can be found at <http://dch.georgia.gov/durb-meeting-information>. Please check back frequently for updates.\***

**New Drugs for Review**

Aptiom

Cycloset

Jardiance

Tanzeum

Trulicity

Anoro Ellipta/Incruse Ellipta

Striverdi Respimat

Otezla

Stelara

Zontivity

Harvoni

Viekira

Plegridy

Uceris

**Supplemental Rebate Classes for Review**

Attention Deficit Hyperactivity Disorder (ADHD) Agents

Opioid Agonist, Partial Agonists

Analgesics, Opioid
Androgens, Anabolic
Anticoagulants
Anticonvulsants
Antidepressants
Antidiabetics, Insulin
Antidiabetics, Non-insulin
Antihemophilic Products
Antihistamines
Antihyperlipidemics
Antihypertensives, Angiotensin Converting Enzyme Inhibitors
Antihypertensives, Angiotensin Receptor Blocker/Calcium Channel Blocker Combinations
Antihypertensives, Angiotensin Receptor Blockers
Antihypertensives, Beta Blockers
Antihypertensives, Calcium Channel Blockers
Antiinfectives, Miscellaneous
Antiinflammatory, Nonsteroidal Antiinflammatory Drugs (NSAIDs)
Antipsychotics
Antivirals, Hepatitis Agents
Biologic Immunomodulators
Biologics, Miscellaneous (Allergen Immunotherapy)
Bronchodilators, Anticholinergics

Bronchodilators, Steroid Inhalants

Bronchodilators, Sympathomimetics

Calcium Regulators, Osteoporosis

Corticosteroids, Oral

Dermatologics, Acne Products

Dermatologics, Antiinflammatory Agents

Dermatologics, Antipsoriatics

Dermatologics, Scabicides/Pediculocides

Digestive Enzymes

Epinephrine Pens

Estrogens

Fibromyalgia Agents

Gastrointestinal, Inflammatory Bowel Agents

Gastrointestinal, Irritable Bowel Syndrome Agents

Gastrointestinal, Proton Pump Inhibitors

Growth Hormones

Hematopoietic, Growth Factors

Migraine Products

Multiple Sclerosis Agents

Multivitamins, Prenatal

Nasal Steroids

Ophthalmics, Adrenergic Agents

Ophthalmics, Antiallergics

Ophthalmics, Antibiotic-Steroid Combinations
Ophthalmics, Antiinfectives
Ophthalmics, Antiinflammatory Drugs
Ophthalmics, Beta Blockers
Ophthalmics, Prostaglandins
Otic Antiinfectives
Platelet Aggregation Inhibitors
Pulmonary Hypertension Drugs
Smoking Deterrents
Urinary Antispasmodics
Urinary Prostatic Hypertrophy
Vaginal Antiinfectives

**\*This list may change at any time. If a supplemental rebate class is not listed above, the class will be reviewed at the June 4<sup>th</sup> meeting. In addition, any drugs/classes listed above that the DURB is not able to complete at the March 26<sup>th</sup> meeting will be reviewed at the June 4<sup>th</sup> meeting. Manufacturers that already presented these drugs at the February Manufacturers' Forum will not need to present again at the April Manufacturers' Forum. Information on the Manufacturers' Forum can be found at <http://dch.georgia.gov/durb-meeting-information>. Please check back frequently for updates.\***